Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism.

D'Agostino C, Zonzin P, Enea I, Gulizia MM, Ageno W, Agostoni P, Azzarito M, Becattini C, Bongarzoni A, Bux F, Casazza F, Corrieri N, D'Alto M, D'Amato N, D'Armini AM, De Natale MG, Di Minno G, Favretto G, Filippi L, Grazioli V, Palareti G, Pesavento R, Roncon L, Scelsi L, Tufano A.

Eur Heart J Suppl. 2017 May;19(Suppl D):D309-D332. doi: 10.1093/eurheartj/sux030. Epub 2017 May 2.

2.

D-dimer level for predicting the in-hospital mortality in liver cirrhosis: A retrospective study.

Li Y, Qi X, Li H, Dai J, Deng H, Li J, Peng Y, Liu X, Sun X, Guo X.

Exp Ther Med. 2017 Jan;13(1):285-289. doi: 10.3892/etm.2016.3930. Epub 2016 Nov 28.

3.

Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study.

Yu J, Li D, Lei D, Yuan F, Pei F, Zhang H, Yu A, Wang K, Chen H, Chen L, Wu X, Tong X, Wang Y.

PLoS One. 2016 Nov 11;11(11):e0165390. doi: 10.1371/journal.pone.0165390. eCollection 2016.

4.

Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines.

Min SK, Kim YH, Joh JH, Kang JM, Park UJ, Kim HK, Chang JH, Park SJ, Kim JY, Bae JI, Choi SY, Kim CW, Park SI, Yim NY, Jeon YS, Yoon HK, Park KH.

Vasc Specialist Int. 2016 Sep;32(3):77-104. Epub 2016 Sep 30. Review.

5.

Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study.

Bang OY, Chung JW, Lee MJ, Kim SJ, Cho YH, Kim GM, Chung CS, Lee KH, Ahn MJ, Moon GJ.

PLoS One. 2016 Jul 18;11(7):e0159170. doi: 10.1371/journal.pone.0159170. eCollection 2016.

6.

An Intact Dissecting Baker's Cyst Mimicking Recurrent Deep Vein Thrombosis.

Jamshed S, Snyder LM.

J Investig Med High Impact Case Rep. 2016 May 13;4(2):2324709616650703. doi: 10.1177/2324709616650703. eCollection 2016 Apr-Jun.

7.

Impact of D-Dimer for Prediction of Incident Occult Cancer in Patients with Unprovoked Venous Thromboembolism.

Han D, ó Hartaigh B, Lee JH, Cho IJ, Shim CY, Chang HJ, Hong GR, Ha JW, Chung N.

PLoS One. 2016 Apr 13;11(4):e0153514. doi: 10.1371/journal.pone.0153514. eCollection 2016.

8.

Association between D-dimer level and portal venous system thrombosis in liver cirrhosis: a retrospective observational study.

Dai J, Qi X, Peng Y, Hou Y, Chen J, Li H, Guo X.

Int J Clin Exp Med. 2015 Sep 15;8(9):15296-301. eCollection 2015.

9.

Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.

Marik PE, Cavallazzi R.

PLoS One. 2015 Nov 20;10(11):e0143252. doi: 10.1371/journal.pone.0143252. eCollection 2015. Review.

10.

Gene microarray analyses for potential biomarkers of single and recurrent venous thromboembolism.

Zhou W, Zhang K, Chen D, Gao P, Wang Q.

Mol Med Rep. 2015 Nov;12(5):7358-66. doi: 10.3892/mmr.2015.4349. Epub 2015 Sep 22.

11.

Assessing the risk of recurrent venous thromboembolism--a practical approach.

Fahrni J, Husmann M, Gretener SB, Keo HH.

Vasc Health Risk Manag. 2015 Aug 17;11:451-9. doi: 10.2147/VHRM.S83718. eCollection 2015. Review.

12.

Long-term prognosis and related factors towards patients with acute pulmonary thromboembolism.

Gong X, Duan Z, Yuan Y.

Int J Clin Exp Med. 2015 May 15;8(5):7906-13. eCollection 2015.

13.

The role of soluble fibrin during anticoagulant therapy: a case report.

Kawakami T, Tanaka N, Ishihara H, Ohno H.

Thromb J. 2015 Jul 6;13:23. doi: 10.1186/s12959-015-0053-1. eCollection 2015.

14.

Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke.

Jang H, Lee JJ, Lee MJ, Ryoo S, Yoon CH, Kim GM, Chung CS, Lee KH, Bang OY, Kim SJ.

J Oncol. 2015;2015:502089. doi: 10.1155/2015/502089. Epub 2015 May 7.

15.

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.

Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N; RAPS Trial Protocol Collaborators.

Lupus. 2015 Sep;24(10):1087-94. doi: 10.1177/0961203315581207. Epub 2015 May 4.

16.

Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Barnes GD, Kanthi Y, Froehlich JB.

Vasc Med. 2015 Apr;20(2):143-52. doi: 10.1177/1358863X14566429. Review.

17.

Diagnosis of deep vein thrombosis, and prevention of deep vein thrombosis recurrence and the post-thrombotic syndrome in the primary care medicine setting anno 2014.

Michiels JJ, Michiels JM, Moossdorff W, Lao M, Maasland H, Palareti G.

World J Crit Care Med. 2015 Feb 4;4(1):29-39. doi: 10.5492/wjccm.v4.i1.29. eCollection 2015 Feb 4. Review.

18.

Duration of anticoagulation for venous thromboembolic events.

Smilowitz NR, Mega JL, Berger JS.

Circulation. 2014 Dec 23;130(25):2343-8. doi: 10.1161/CIRCULATIONAHA.114.010456. Review. No abstract available.

19.

Clinical update on pulmonary embolism.

Duru S, Keleşoğlu A, Ardıç S.

Arch Med Sci. 2014 Jun 29;10(3):557-65. doi: 10.5114/aoms.2013.34325. Epub 2013 May 7.

20.

Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study.

Nagler M, Bachmann LM, Schmid P, Raddatz Müller P, Wuillemin WA.

PLoS One. 2014 Apr 18;9(4):e95761. doi: 10.1371/journal.pone.0095761. eCollection 2014.

Supplemental Content

Support Center